Drug Reprofiling to Identify Potential HIV-1 Protease Inhibitors

The use of protease inhibitors in human immunodeficiency virus type 1 (HIV-1) treatment is limited by adverse effects, including metabolic complications. To address these challenges, efforts are underway in the pursuit of more potent and less toxic HIV-1 protease inhibitors. Repurposing existing dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Okafor, Sunday N., Meyer, Abigail, Gadsden, Jay, Ahmed, Fadi, Guzmán, Lilian, Ahmed, Hashim, Romero, José A. Fernández, Angsantikul, Pavimol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488881/
https://www.ncbi.nlm.nih.gov/pubmed/37687159
http://dx.doi.org/10.3390/molecules28176330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10488881/
https://www.ncbi.nlm.nih.gov/pubmed/37687159
http://dx.doi.org/10.3390/molecules28176330

Ejemplares similares